In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

The Emperor of All Maladies reveals the many faces of an iconic, shape-shifting disease that is the defining plague of our generation. The story of cancer is a story of human ingenuity, resilience, and perseverance but also of hubris, arrogance, paternalism, and misperception, all leveraged against a disease that, just three decades ago, was thought to be easily vanquished in an all-out "war against cancer".

When Elon Musk was a kid in South Africa, he was regularly beaten by bullies. One day a group pushed him down some concrete steps and kicked him until his face was a swollen ball of flesh. He was in the hospital for a week. But the physical scars were minor compared to the emotional ones inflicted by his father, an engineer, rogue, and charismatic fantasist.

When Michael Lewis first met him, Sam Bankman-Fried was the world’s youngest billionaire and crypto’s Gatsby. CEOs, celebrities, and leaders of small countries all vied for his time and cash after he catapulted, practically overnight, onto the Forbes billionaire list. Who was this rumpled guy in cargo shorts and limp white socks, whose eyes twitched across Zoom meetings as he played video games on the side?

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

Beginning with opium, the “joy plant,” which has been used for 10,000 years, Thomas Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book.

From the author of The Emperor of All Maladies, winner of the Pulitzer Prize, and The Gene, a #1 New York Times bestseller, comes his most spectacular book yet, an exploration of medicine and our radical new ability to manipulate cells. Rich with Mukherjee’s revelatory and exhilarating stories of scientists, doctors, and the patients whose lives may be saved by their work, The Song of the Cell is the third book in this extraordinary writer’s exploration of what it means to be human.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made “the impossible possible”—creating, testing, and manufacturing a safe and effective COVID-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer overcame a series of crises that were compounded by social and political unrest.

The bestselling author of Leonardo da Vinci and Steve Jobs returns with a “compelling” (The Washington Post) account of how Nobel Prize winner Jennifer Doudna and her colleagues launched a revolution that will allow us to cure diseases, fend off viruses, and have healthier babies.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion.

Ray Dalio does not want you to listen to this audiobook. Late last year, when the billionaire founder of Bridgewater Associates, the largest hedge fund on the planet, announced that he was stepping down from the company he started out of his apartment nearly 50 years ago, the news made headlines around the world. Dalio cultivated an aura of international admiration and fame thanks to his company’s eye-popping success, coupled with a mystique he encouraged with frequent media appearances, celebrity hobnobbing, and his bestselling book, Principles.

You wake up and feel a tickle in your throat. Your head hurts. You’re mildly annoyed as you get the kids ready for school and dress for work yourself. Meanwhile, an epic war is being fought, just below your skin. Millions are fighting and dying for you to be able to complain as you head out the door. So what, exactly, is your immune system? In Immune, Philipp Dettmer, the brains behind the most popular science channel on YouTube, takes listeners on a journey through the fortress of the human body and its defenses.

From an award-winning Fortune reporter, an explosive narrative investigation of the generic drug boom that reveals the life-threatening dangers posed by globalization - The Jungle for pharmaceuticals.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug and how the core team—denied their share of the profits—went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

The search to find medicines is as old as disease, which is to say as old as the human race. Through serendipity - by chewing, brewing, and snorting - some Neolithic souls discovered opium, alcohol, snakeroot, juniper, frankincense, and other helpful substances. Ötzi the Iceman, the 5,000-year-old hunter frozen in the Italian Alps, was found to have whipworms in his intestines and Bronze Age medicine, a worm-killing birch fungus, knotted to his leggings.

Pharmaceutical breakthroughs such as antibiotics and vaccines rank among some of the greatest advancements in human history. Yet, exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on prescription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry.

From an award-winning Fortune reporter, an explosive narrative investigation of the generic drug boom that reveals the life-threatening dangers posed by globalization - The Jungle for pharmaceuticals.

We humans like to think of ourselves as highly evolved creatures. But if we are supposedly evolution's greatest creation, why do we have such bad knees? Why do we catch head colds so often - 200 times more often than a dog does? How come our wrists have so many useless bones? And are we really supposed to swallow and breathe through the same narrow tube? Surely there's been some kind of mistake. As professor of biology Nathan H. Lents explains in Human Errors, our evolutionary history is nothing if not a litany of mistakes, each more entertaining and enlightening than the last.

An Epidemic of Absence asks what will happen in developing countries, which, as they become more affluent, have already seen an uptick in allergic disease: Will India end up more allergic than Europe? Velasquez-Manoff also details a controversial underground movement that has coalesced around the treatment of immune-mediated disorders with parasites. Against much of his better judgment, he joins these do-it-yourselfers and reports his surprising results.

Today, astonishing surgical breakthroughs are making limb transplants, face transplants, and a host of other previously undreamed-of operations possible. But getting here has not been a simple story of medical progress. In Blood and Guts, veteran science writer Richard Hollingham weaves a compelling narrative from the key moments in surgical history. We have a ringside seat in the operating theater of University College Hospital in London as world-renowned Victorian surgeon Robert Liston performs a remarkable amputation in 30 seconds - from first cut to final stitch.

We all know that without water we couldn't survive, and that sometimes a cup of coffee or a glass of wine feels just as vital. But do we really understand how much we rely on liquids, or the destructive power they hold? Set over the course of a flight from London to San Francisco, Liquid Rules offers listeners a fascinating tour of these formless substances, told through the language of molecules, droplets, heartbeats, and ocean waves.

In our unique genomes, every one of us carries the story of our species - births, deaths, disease, war, famine, migration, and a lot of sex. But those stories have always been locked away - until now. Who are our ancestors? Where did they come from? Geneticists have suddenly become historians, and the hard evidence in our DNA has completely upended what we thought we knew about ourselves. Acclaimed science writer Adam Rutherford explains exactly how genomics is completely rewriting the human story - from 100,000 years ago to the present.

Epigenetics can potentially revolutionize our understanding of the structure and behavior of biological life on Earth. It explains why mapping an organism's genetic code is not enough to determine how it develops or acts and shows how nurture combines with nature to engineer biological diversity. Surveying the 20-year history of the field while also highlighting its latest findings and innovations, this volume provides a readily understandable introduction to the foundations of epigenetics.

Aging - not cancer, not heart disease - is the underlying cause of most human death and suffering. The same cascade of biological changes that renders us wrinkled and gray also opens the door to dementia and disease. We work furiously to conquer each individual disease, but we never think to ask: Is aging itself necessary? Nature tells us it is not: There are tortoises and salamanders who are spry into old age and whose risk of dying is the same no matter how old they are.

A gripping journey of discovery, The Catalyst moves from the early experiments that first hinted at RNA's spectacular powers, to Cech's own paradigm-shifting finding that it can catalyze cellular reactions, to the cutting-edge biotechnologies poised to reshape our health.